Close menu

January 9th, 2020 | 05:50 CET

Memphasys, Merck, Novartis - Solutions for the desire to have children

  • Artificial Insemination
Photo credits:

Many couples around the world long for their own children, but for many people, family planning by natural means is not possible. Modern medicine can help in the development of a pregnancy by means of artificial insemination, the so-called in vitro fertilisation, also known as IVF procedure. In this context, egg cells are taken from the woman and artificially fertilised with the man's sperm in the laboratory. If successful, embryos can then be transferred to the uterus. The need for artificial insemination in couples varies between 16 and 25% depending on the region - a large and global market.

time to read: 1 minutes | Author: Mario Hose
ISIN: AU000000MEM5 , DE0006599905 , CH0012005267

Table of contents:

    Oocyte collection and fertilization

    The development of the egg is monitored by ultrasound examinations before the egg is retrieved. After ovulation, the egg is removed from the mature follicles with a fine needle. This process is followed on the screen by ultrasound.

    On the day of collection, the egg and sperm are brought together in a nutrient fluid. Prior to this fertilisation in the laboratory, the seminal fluid is prepared in order to improve the fertilisation ability of the sperm cells. Subsequently, the eggs are to be fertilised in an incubator.

    Transfer of the embryos

    The fertilised eggs spend up to six days in an incubator for further development and the resulting embryos can then be transferred to the uterus. Usually one to three embryos are transferred into the uterus. About two weeks after the embryos are transferred to the uterus, a blood test can be performed to determine whether the pregnancy has begun. Another two weeks later, an ultrasound scan will show whether an embryo is alive and whether it is a single or multiple embryos.

    The chances of success of artificial insemination are higher for non-smoking couples than for smokers. In addition, birth rates also depend on the age of the woman; the younger the woman, the higher the chances. In Germany, the birth rate per treatment cycle fluctuates between 15 and 20%.

    Medical research is working on improvements

    With the product FELIX, Memphasys has developed a solution that enables the rapid separation of high-quality sperm. The more successful the processing of the seminal fluid can be, the higher the birth rates will be. A verification and validation process is currently underway so that sales can start in the second half of 2020.

    In addition to Memphasys, the pharmaceutical companies Merck and Novartis also have various therapeutic options, medical devices and technologies in their portfolio for the IVF procedure. Memphasys has a market value of EUR 25 million, Merck EUR 14.4 billion and Novartis EUR 196.3 billion. Due to the current comparatively low market capitalization, a successful market launch of FELIX may have a positive economic impact for Memphasys.

    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.

    Der Autor

    Mario Hose

    Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.

    About the author